CDD Vault

Prosion Therapeutics is pioneering a new class of small-molecule drugs that make previously “undruggable” protein–protein interactions actionable. Using the CDD Vault platform as its unified ELN and data hub, the team has accelerated ProM discovery, streamlined collaboration across Cologne and Berlin, and advanced a first-in-class inhibitor with demonstrated proof-of-concept in metastatic cancer models.

Explore this data sheet as it guides you on how to register your antibody and antibody drug conjugate (ADC) molecules allowing seamless entity rendering and data capture. Discover how the compose macromolecule editor uploads directly to the CDD Vault® to provide a readable format for all metadata, sequence and structure information.

According to the World Health Organization (WHO), approximately 700,000 people worldwide die from drug-resistant infections each year. Hence, tackling antimicrobial resistance is vital for the pharmaceuticals industry, but managing drug discovery data can be challenging.

Discover how a team at Swiss pharmaceutical company, BioVersys, has used CDD Vault®, a hosted biological and chemical database that allows researchers to securely manage private and external data, for their project targeting MRSA. BioVersys wanted to recapitulate its existing data structures and their relationships and add new ones as the project evolved. By doing so, they were able to view, side-by-side, data from in vitro potency assays, including full-dose response curves in different bacterial strains; absorption, distribution, metabolism, and excretion parameters; chemical structures; and toxicity.

The University of Illinois Collaborative Engagement in Novel Therapeutic Research and Enterprise (UICentre) is the campus-wide drug discovery initiative at the University of Illinois, Chicago. Discover how it has provided its labs with a 'single source of truth' through its deployment of Collaborative Drug Discovery’s CDD Vault – the cloud-based scientific data management system that securely manages both internal and external biological and chemical data. Deployment includes CDD school-wide licensing, freeing individual labs and researchers from having to purchase separate licenses, while providing a unified solution for secure electronic data storage and electronic laboratory notebooks (ELN)s. Explore how this has enhanced collaboration between chemists and biologists and core functionality including chemical registration, structure activity relationship, inventory, visualization, and electronic lab notebook capabilities.

In this whitepaper, Collaborative Drug Discovery outlines how efficient management of diverse, data-driven drug discovery projects can enhance success rates and reduce costs. The overwhelming and discipline-specific data generated by discovery teams can be challenging to interpret. Modern informatics systems like CDD Vault® address this challenge by making data conveniently accessible and offering user-friendly visualization. This is crucial for interdisciplinary teams across various laboratories and geographic locations, ensuring all team members can readily interpret the information, fostering collaboration and project success.

In this case study, Collaborative Drug Discovery details how its CDD Vault®, a hosted drug discovery informatics platform, was adopted by X-Chem. X-Chem's state-of-the-art facility in Montreal, Canada, provides comprehensive support for drug discovery, covering all stages from hit identification to clinical candidate nomination. The company was established to offer highly efficient capabilities and experienced personnel to accelerate clients' projects securely and economically. CDD Vault manages both private and external biological and chemical data for X-Chem, ensuring reliable and secure advancement of its initiatives.

In this case study, Collaborative Drug Discovery highlights Opna Bio's utilization of the CDD Vault® Registration System and ELN as the central repository for its extensive preclinical data. Opna Bio, founded in 2019 in Lausanne, Switzerland, concentrates on discovering and developing small molecule oncology therapeutics. Its portfolio encompasses early discovery to mid-clinical stage small molecule drug programs specifically designed to target cancer hallmarks.

In this case study, Collaborative Drug Discovery discusses Psylo's utilization of the CDD Vault® registration system and ELN. Psylo, a company focused on developing new drugs for psychiatric disorders, has adopted these platforms as its central repository. These systems help Psylo store, characterize, and manage its libraries, structure activity relationship (SAR) data, as well as in vitro and other experimental and screening assay data. Psylo's approach involves redesigning existing families of psychedelic compounds into entirely new chemical entities (NCEs) for its drug portfolio.

In this case study, Collaborative Drug Discovery highlights Standigm's utilization of the CDD Vault® informatics platform as a central data management infrastructure for its drug discovery efforts. Standigm, an AI-driven drug discovery company based in Seoul, develops advanced machine learning algorithms and AI-based workflows. These innovations, integrated with the CDD Vault, help streamline the drug discovery process, utilizing big data and new analytical capabilities to accelerate outcomes while minimizing guesswork.

In this case study, Collaborative Drug Discovery showcases how Via Nova Therapeutics implemented CDD Vault® to securely manage both its internal and external biological and chemical data. Via Nova Therapeutics utilizes cutting-edge drug discovery methods, including phenotypic and biochemical screening, structure-based drug design, and targeting essential host factors, to identify novel antivirals for the specific infections it studies.

August 7, 2025, 08:00 BST / 09:00 CEST / 15:00 CST / 16:00 JST

Reliance on informatic platforms in drug discovery has become essential for managing complex data, generating actionable insights, and improving decision-making across every stage of development. Now, with the integration of AI and machine learning (ML), informatics is advancing even further to revolutionize pharmaceutical R&D.

Join our exciting line up of speakers with Dr. Barry Bunin, CEO, Collaborative Drug Discovery, Dr. Dimitris Agrafiotis, Director of Digital Analytics & AI, Arsenal Capital Partners, and Dr. Chris Waller, VP and Chief Scientist, EPAM Systems, for an expert discussion on how AI and ML have transformed drug discovery informatics to support both academic labs and global organizations.

Plus, watch a demonstration of CDD Vault's AI capabilities. Janice Darlington, Customer Engagement Scientist at CDD, will showcase practical applications in drug discovery workflows.

Key learning objectives:

• Understand current trends in pharmaceutical informatics and how they impact different organizational scales.
• Evaluate strategies for implementing and integrating modern informatics solutions with legacy systems.
• Assess the role of AI/ML technologies in drug discovery and their practical implementation.
• Identify key considerations for selecting and deploying informatics platforms in pharmaceutical R&D.

Who should attend?

• Industry professionals: Pharma R&D experts, including drug chemists, biologists, data scientists, AI/ML specialists, and informatics leads.
• Academics and strategic leaders: Computational and informatics scientists, lab directors, research managers, and VP-level executives driving R&D strategy and informatics investment decisions.

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

In the attempt of treating all human diseases, the realization of a cohort of targets being deemed as ‘undruggable’ is a growing market in therapeutics. With more and more researchers focusing on these targets, it has unveiled the opportunity to expand our knowledge of these larger and more complex proteins that fail to fit into conventional drug design strategies.

‘Out-of-the-box’ approaches are driving pharmaceutical developments forward with encouraging results. Join Dr. Bernhard Fasching, of Monte Rosa Therapeutics and Dr, Benedict Cross, of PhoreMost Therapeutics, as they share the promising new modalities in drug discovery, unveiling strategies and technologies aimed at targeting previously ‘undruggable’ diseases.

This webinar offers valuable insights for both seasoned researchers and newcomers, enhancing their understanding of the latest advancements in drug discovery, including topics of molecular glue degraders and editing the proteome.

Key learning objectives

• Discover the latest advancements in drug discovery
• Gain insight into molecular glue degraders (features and origins)
• Learn more about targeted protein degradation (editing the proteome)

Who should attend

Researchers in drug discovery, researchers working with ‘undruggable targets’.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Learn about a data management solution from Collaborative Drug Discovery’s (CDD’s), the CDD Vault®. This cloud-based software is designed to seamlessly capture, manage, and analyze data from diverse research projects. Features including robust activity and registration functionalities for compounds, antibodies, plasmids, and more. With data visualization and an integrated electronic laboratory notebook, CDD Vault facilitates efficient collaboration within multidisciplinary teams, both internally and externally. Experience the convenience of having all your research data consolidated in one secure place, empowering you to make informed decisions regarding the progression of compounds in the pipeline or the continuation of research initiatives.

This video was filmed at SLAS2024.

In this video from Collaborative Drug Discovery, Inc., explore the CDD Vault® platform, a data management tool scientists use to store, mine, analyze, and collaborate on their research. In this product demo, explore the kind of data users store in their own private and secure CDD Vaults. These can include nucleotide and amino acid sequences, chemical properties, sets of configurable user-defined fields, and much more.

In this video from Collaborative Drug Discovery, Inc., explore the CDD Vault® platform, a data management tool scientists use to store, mine, analyze, and collaborate on their research. In this product demo, explore the kind of data users store in their own private and secure CDD Vaults. These can include small molecule structures, chemical properties, sets of configurable user-defined fields, and much more.

inCerebro enhances CDD's capabilities in managing, sharing, and analysing complex research data, from its proprietary inCerebro MIND platform (Modelling with Intelligence for Novel Drugs).

Learn how CDD’s AI search tool offers a rapid and secure means to discover and optimize promising drug candidates